Danaher (NYSE:DHR) Announces Earnings Results, Beats Estimates By $0.09 EPS

Danaher (NYSE:DHR) posted its earnings results on Tuesday. The conglomerate reported $2.23 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09, Zacks reports. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.84 billion for the quarter, compared to analysts’ expectations of $6.79 billion. During the same quarter in the prior year, the company posted $2.14 earnings per share. Danaher’s revenue for the quarter was up 4.6% compared to the same quarter last year.

Danaher Stock Down 2.3%

Danaher stock traded down $5.32 during mid-day trading on Wednesday, hitting $230.44. The company had a trading volume of 2,373,624 shares, compared to its average volume of 3,321,527. The business has a fifty day moving average of $230.80 and a 200 day moving average of $213.70. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The stock has a market cap of $162.77 billion, a price-to-earnings ratio of 47.58, a PEG ratio of 3.60 and a beta of 0.89. Danaher has a 1 year low of $171.00 and a 1 year high of $242.80.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is currently 26.39%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Robust Q4 and analyst buy reaffirmation — William Blair’s Matt Larew kept a Buy rating, citing a strong Q4 beat and a credible 2026 growth outlook that underpin confidence in the company’s trajectory. Danaher: Robust Q4 Beat and Credible 2026 Growth Outlook Underpin Buy Rating
• Positive Sentiment: Q4 results topped estimates — Danaher reported EPS of $2.23 and revenue growth (~+4.6% YoY), beating consensus expectations, which supports near‑term earnings momentum. Danaher (DHR) Beats Q4 Earnings and Revenue Estimates
• Positive Sentiment: Media/TV endorsement — Jim Cramer highlighted Danaher as likely to produce a strong quarter, which can drive retail interest and short‑term buying pressure. Jim Cramer on Danaher: “This Could Be the First Truly Strong Quarter in Years”
• Neutral Sentiment: FY‑2026 EPS guidance in line with street — Danaher guided to $8.350–8.500 EPS for FY‑2026, which essentially brackets consensus (~8.42) and reduces surprise risk but doesn’t represent an upside beat. Danaher forecasts 2026 profit in line with estimates on pharma spending recovery
• Neutral Sentiment: Full release and presentation materials available — the company published the PR release and slide deck with segment detail; useful for modeling but no additional material surprises. Danaher Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Ongoing headwinds in academic research funding — management noted weakness in academic research markets persists, which could pressure parts of the life‑science portfolio if not offset by pharma recovery. Danaher forecasts 2026 profit in line with estimates on pharma spending recovery

Insiders Place Their Bets

In other news, Director Teri List sold 3,298 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This represents a 13.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 30,248 shares of company stock worth $6,609,663 over the last three months. 11.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. JPL Wealth Management LLC acquired a new position in Danaher during the 3rd quarter valued at about $25,000. WFA of San Diego LLC purchased a new position in shares of Danaher in the 2nd quarter worth approximately $26,000. Militia Capital Partners LP bought a new stake in shares of Danaher during the 3rd quarter valued at $59,000. Zuckerman Investment Group LLC purchased a new position in Danaher during the 2nd quarter valued at about $222,000. Finally, Banco BTG Pactual S.A. bought a new position in shares of Danaher during the third quarter valued at approximately $225,000. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DHR has been the subject of several recent analyst reports. Rothschild & Co Redburn reiterated a “neutral” rating and issued a $220.00 price objective (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Jefferies Financial Group upped their price target on shares of Danaher from $245.00 to $255.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Redburn Partners set a $220.00 price target on shares of Danaher in a report on Wednesday, October 8th. KeyCorp reiterated an “overweight” rating on shares of Danaher in a research report on Thursday, December 18th. Finally, Leerink Partners increased their price objective on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research report on Friday, January 16th. Twenty investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $252.09.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.